Product name
Elara Pharmaceuticals is offering tubulin polymerization inhibitors and allosteric Aurora A kinase inhibitorsSummary
New classes of inhibitors for cancer therapy targeting Aurora A kinase and Estrogen Receptor signalling via mechanistically new routes.Organization name
ELARA Pharmaceuticals GmbHProfile
ELARA Pharmaceuticals GmbH is an early stage drug discovery and development company, incorporated 2006 in Germany.
Building on the pioneering work at EMBL, Heidelberg, on Estrogen signaling and allosteric kinase inhibition, ELARA has four chemotypes in lead optimization with a broad indication range and the potential of lower toxicity due to their unique modes of action.
Their most advanced candidate is orally bioavailable and indicated for the treatment of multiple myeloma, a cancer that clearly lacks efficacious therapies. ELARA foresees an IND filing by Q1 2010 and initiation of human proof of concept trials.
ELARA has developed a robust pre-clinical pipeline with sets of promising molecules. These are directed at a number of clinically validated and also novel targets like Aurora kinases and cellular factors involved in Estrogen Receptor signaling, which are expected to open new therapeutic perspectives in oncology.
ELR105813
is an orally bioavailable tubulin polymerization inhibitor targeting the colchicine binding site. It has a broad spectrum of activity in vitro against a diverse set of tumour cell lines. ERL105813 is well tolerated in vivo and shows superior pharmacokinetic profile compared to ABT-571, a phase II compound with similar mechanism of action. Xenograft studies are ongoing and initial data is expected by end of 2007.
ELR510052
a second chemotype targeting the colchicine binding site of tubulin. They have reason to believe that this second generation of tubulin inhibitors will show enhanced in vivo profile compared to the competition. Proof of efficacy results are expected in Q1 2008.
ERL144949
targets tubulin polymerization through an indirect mechanism. This chemotype show good levels of in vitro activity against a diverse set of tumor cell lines. Current efforts are focused on optimization for physicochemical properties.
Allosteric Kinase Inhibitors: Aurora
Ground breaking research from EMBL research groups enabled the identification of a novel allosteric regulatory site of Aurora A kinase that is essential for proper protein function. In our Aurora program, we established a proprietary portfolio of allosteric inhibitor chemotypes.
More information can be found under www.elarapharma.com.
Meet the company at BioVaria 2008 www.biovaria.net
Contact
Elara Pharmaceuticals GmbH
Dr. Joe Lewis
j.lewis(at)elarapharma
About ELARA Pharmaceuticals GmbH
ELARA Pharmaceuticals GmbH is an early stage drug discovery and development company, incorporated 2006 in Germany. Based on outstanding scientific research, which originates from the European Molecular Biology Laboratory (EMBL) in Heidelberg, ELARA´s mission is to provide novel and efficacious medicines for the treatment of cancers with high unmet medical need.
Seed capital was invested by EMBL Ventures and intellectual property licensed via EMBL Enterprise Management (EMBLEM). Additional funding was granted in 2007 by the German Federal Ministry of Education and Research (BMBF) under its GOBio initiative. Currently ELARA is located on the EMBL campus in close proximity to the founder´s labs.
Description File
Tubulin_polymerization_inhibitors_and_allosteric_Aurora_A_kinase_inh...
print this page
